Biotech | October 28, 2021
MSD and MPP sign licensing agreement to make molnupiravir affordable
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
The collaboration aims to deliver greater insights to the oncology fraternity, predict patient therapy responses and enable therapy selection resulting in optimal treatment outcomes.
It answers the most basic questions from a patient’s perspective
The list of kids with co-morbidities eligible for vaccination would be announced by the government
Through the mission an entire ecosystem for services from treatment to critical research will be created in every corner of the country
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
Pluss Advanced Technologies (PLUSS), has led the growth of energy storage materials across applications. Their proprietary Phase Change Material has gained wide acceptance in the pharmaceutical, logistics and food industries. The varied demands of the industry during Covid-19 has brought its technology into focus. Samit Jain, MD, PLUSS in conversation with Thomas C Thottathil discusses trends and outlines his plans for the business
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
The new products include the COAG Line automated, semi-automated and POC systems manufactured by Diagon Hungary
Subscribe To Our Newsletter & Stay Updated
